Prenatal whole-exome sequencing in fetuses with increased nuchal translucency.

chromosomal microarray analysis genetic counseling increased nuchal translucency prenatal diagnosis whole-exome sequencing

Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 19 04 2023
received: 30 01 2023
accepted: 12 07 2023
medline: 20 11 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

Increased nuchal translucency (NT) is associated with an increased risk for genetic disorders. The aim of this study was to investigate the value of whole-exome sequencing (WES) in detecting genetic abnormalities for fetuses with isolated first-trimester increased NT. After the exclusion of aneuploidies and pathogenic copy number variants (CNVs) by quantitative fluorescent polymerase chain reaction (QF-PCR) and chromosomal microarray analysis (CMA), WES was performed on 63 fetuses with isolated first-trimester increased NT (≥3.5 mm). Overall, WES yielded a 4.8% (3/63) diagnostic rate for fetuses with isolated increased NT. Pathogenic variants were identified in 37.5% (3/8) fetuses that developed additional structural anomalies later in gestation, and no pathogenic variants were detected in increased NT that resolved or remained isolated throughout the pregnancy. This study provides powerful evidence to offer prenatal WES for increased NT only when additional abnormalities are present. Early detailed ultrasound to detect emerging anomalies can help physicians offer prenatal WES to fetuses with a greater likelihood of diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
Increased nuchal translucency (NT) is associated with an increased risk for genetic disorders. The aim of this study was to investigate the value of whole-exome sequencing (WES) in detecting genetic abnormalities for fetuses with isolated first-trimester increased NT.
METHODS METHODS
After the exclusion of aneuploidies and pathogenic copy number variants (CNVs) by quantitative fluorescent polymerase chain reaction (QF-PCR) and chromosomal microarray analysis (CMA), WES was performed on 63 fetuses with isolated first-trimester increased NT (≥3.5 mm).
RESULTS RESULTS
Overall, WES yielded a 4.8% (3/63) diagnostic rate for fetuses with isolated increased NT. Pathogenic variants were identified in 37.5% (3/8) fetuses that developed additional structural anomalies later in gestation, and no pathogenic variants were detected in increased NT that resolved or remained isolated throughout the pregnancy.
CONCLUSION CONCLUSIONS
This study provides powerful evidence to offer prenatal WES for increased NT only when additional abnormalities are present. Early detailed ultrasound to detect emerging anomalies can help physicians offer prenatal WES to fetuses with a greater likelihood of diagnosis.

Identifiants

pubmed: 37766479
doi: 10.1002/mgg3.2246
pmc: PMC10655512
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2246

Subventions

Organisme : Natural Science Foundation of Xinjiang Province
ID : 2018D01A50

Informations de copyright

© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Lancet. 2019 Feb 23;393(10173):758-767
pubmed: 30712878
Ultrasound Obstet Gynecol. 2001 Dec;18(6):610-4
pubmed: 11844199
Obstet Gynecol. 2016 May;127(5):e108-e122
pubmed: 26938573
Ultrasound Obstet Gynecol. 2011 Jan;37(1):116-26
pubmed: 20842655
Cell. 2012 Apr 27;149(3):525-37
pubmed: 22521361
Prenat Diagn. 2020 Jan;40(2):197-205
pubmed: 31697852
Ultrasound Obstet Gynecol. 2019 Jan;53(1):80-86
pubmed: 29947050
Ultrasound Obstet Gynecol. 2018 Apr;51(4):493-502
pubmed: 28976722
Diagnostics (Basel). 2022 Dec 23;13(1):
pubmed: 36611340
Prenat Diagn. 2021 Oct;41(11):1401-1413
pubmed: 34091931
Genet Med. 2020 Apr;22(4):675-680
pubmed: 31911674
J Med Genet. 2019 Oct;56(10):654-661
pubmed: 31040167
Genet Med. 2019 Apr;21(4):769-771
pubmed: 30578420
Obstet Gynecol. 2016 Dec;128(6):e262-e268
pubmed: 27875474
Prenat Diagn. 2017 Aug;37(8):750-753
pubmed: 28569377
Front Genet. 2021 Apr 09;12:616392
pubmed: 33897756
Genet Med. 2021 Aug;23(8):1381-1390
pubmed: 34012068
Prenat Diagn. 2010 Feb;30(2):93-102
pubmed: 20077440
J Clin Med. 2014 Sep 12;3(3):1018-32
pubmed: 26237491
J Obstet Gynaecol Can. 2011 Sep;33(9):955-960
pubmed: 21923994
Genet Med. 2021 Jun;23(6):1116-1124
pubmed: 33568805
Lancet Respir Med. 2015 May;3(5):377-87
pubmed: 25937001
Br J Obstet Gynaecol. 1994 Sep;101(9):782-6
pubmed: 7947527
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Sci Transl Med. 2012 Oct 3;4(154):154ra135
pubmed: 23035047
Lancet. 2019 Feb 23;393(10173):747-757
pubmed: 30712880
Front Med (Lausanne). 2021 Oct 18;8:737936
pubmed: 34733861
Genes (Basel). 2022 Aug 24;13(9):
pubmed: 36140685
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cytogenet Genome Res. 2020;160(2):57-62
pubmed: 32036363
BMJ. 2006 Feb 25;332(7539):452-5
pubmed: 16476673
Ultrasound Obstet Gynecol. 2007 Jul;30(1):11-8
pubmed: 17559183
Am J Obstet Gynecol. 2005 Apr;192(4):1005-21
pubmed: 15846173
Prenat Diagn. 2020 Oct;40(11):1426-1431
pubmed: 32668055
Eur J Obstet Gynecol Reprod Biol. 2020 Aug;251:119-124
pubmed: 32502767
Genes (Basel). 2022 Apr 21;13(5):
pubmed: 35627109
N Engl J Med. 2020 Oct 29;383(18):1746-1756
pubmed: 33027564
Ultrasound Obstet Gynecol. 2017 May;49(5):592-598
pubmed: 27183961
Ultrasound Obstet Gynecol. 2015 Dec;46(6):650-8
pubmed: 25900824
Front Genet. 2019 Aug 16;10:761
pubmed: 31475041
Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:164-7
pubmed: 26771907
Mol Genet Genomic Med. 2023 Nov;11(11):e2246
pubmed: 37766479
Genet Med. 2017 Nov;19(11):1207-1216
pubmed: 28518170
BJOG. 2022 Jan;129(1):52-61
pubmed: 34411415
Genet Med. 2021 Nov;23(11):2230
pubmed: 33731880
Ultrasound Obstet Gynecol. 2013 Jan;41(1):102-13
pubmed: 23280739
Prenat Diagn. 2015 Oct;35(10):1010-7
pubmed: 26275891
Ultrasound Obstet Gynecol. 2008 Apr;31(4):376-83
pubmed: 18383462
Ultrasound Obstet Gynecol. 2020 Mar;55(3):383-390
pubmed: 31115076

Auteurs

Chunge Cao (C)

Prenatal Diagnosis Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Fang Liu (F)

Prenatal Diagnosis Center, Chongqing Maternal and Child Healthcare Hospital, Chongqing, China.

Yan Yang (Y)

Prenatal Diagnosis Center, West China Second University Hospital, Sichuan University, Chengdu, China.

Qing Zhang (Q)

Prenatal Diagnosis Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Junfang Huang (J)

Department of Obstetrics and Gynecology, Maternal and Child Healthcare Hospital of Longhua District, Shenzhen, China.

Xinhong Liu (X)

Department of Obstetrics and Gynecology, Maternal and Child Healthcare Hospital of Longhua District, Shenzhen, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH